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SUMMARY
Retinal ganglion cell (RGC) death is the hallmark of glaucoma. Axonal injury is thought to precede RGC loss in glaucoma, and thus studies using an optic nerve (ON) crush model have been widely used to investigate mechanisms of cell death that are common to both conditions. Prior work has focused on the involvement of caspases in RGC death, but little is known about the contribution of other forms of cell death such as necrosis. In this study we show that receptor interacting protein (RIP) kinase-mediated necrosis normally plays a role in RGC death and acts in concert with caspase-dependent apoptosis.
The expression of RIP3, a key activator of RIP1 kinase, as well as caspase activity, increased following ON injury. Caspase inhibition alone failed to provide substantial protection to injured RGCs and unexpectedly exacerbated necrosis. In contrast, pharmacologic or genetic inhibition of RIP kinases in combination with caspase blockade delayed both apoptotic and necrotic RGC death, although RGCs still continued to die.
Furthermore, inhibition of RIP1 kinase promoted a moderate level of axon regeneration that was only minimal affected by caspase inhibition. In conclusion, multiple approaches are required for effective RGC death prevention and axonal regeneration. Further studies are needed to elucidate more effective long term strategies that can lead to sustained neuroprotection and regeneration.
HIGHLIGHTS
• Caspase inhibition alone does not provide extensive protection against RGC death following optic nerve damage.
• RIP kinase-mediated necrosis is a redundant death pathway in RGCs.
• Combined inhibition of caspases and RIP kinases transiently increases RGC survival.
• Necrosis inhibitors promote a moderate level of axonal regeneration.
INTRODUCTION
Glaucoma affects 70 million people worldwide (1, 2) and is characterized by optic nerve (ON) atrophy and the progressive death of retinal ganglion cells (RGCs) (3). Glaucoma is often associated with elevated intraocular pressure (IOP), and current management aims at lowering IOP (4). Yet although IOP-lowering treatments slow the development and progression of glaucoma, approximately 10% of people who receive proper treatment continue to experience loss of vision (2). Therefore, understanding the underlying mechanisms involved in RGC death could potentially lead to novel therapeutic approaches.
In general, cell death occurs through two major, morphologically distinct processes, apoptosis, and necrosis (5). Apoptosis is characterized by cellular shrinkage and nuclear condensation, and the caspase family plays a central role in this process (6). In contrast, necrosis is accompanied by cellular and organellar swelling and plasma membrane rupture, and has been considered an uncontrolled form of cell death. However, recent evidence indicates that some necrosis can be executed by regulated signal transduction pathways such as those mediated by receptor interacting protein (RIP) kinases (7, 8) . Although previous reports have identified the involvement of apoptosis in RGC death in glaucoma (9), little is known about the contribution of other forms of cell death to the demise of RGCs.
RIP1 is a death domain-containing protein that possesses serine/threonine kinase activity and is a key regulator of cell fate in response to the stimulation of death-domain receptors such as the tumor necrosis factor (TNF) receptor (10). RIP1 forms a death inducing signaling complex with Fas-associated death domain and caspase-8 after stimula-tion of TNF-α, and mediates caspase-dependent apoptosis. On the other hand, when caspases are inhibited or cannot be activated efficiently, RIP1 induces necrosis instead of apoptosis through RIP1-RIP3 binding and phosphorylation of their kinase domain (11) (12) (13) (14) (15) .
We have previously demonstrated that TNF-α is a significant mediator of RGC death in animal models of glaucoma, with levels rising sharply as a result of elevated intraocular pressure, which leads to an inflammatory response (16) (17) . Clinically, TNF-α is up-regulated within RGCs and ON axons of glaucomatous eyes (18), and several other lines of evidence suggest the involvement of TNF-α signaling in glaucoma (19). However, which cell death pathways are utilized in the execution of RGC death are not fully elucidated. Other studies have investigated the role of caspases and their inhibition in protection of RGC cell death and in axonal regeneration (20) (21, 22) (23-25) . In general, these studies show that blocking caspases delays but does not fully attenuate the loss of RGCs(26) , though a more recent study points to more impressive gains in cell survival (22) In this study, we investigated the role of RIP-mediated necrosis in addition to the role of caspase-mediated apoptosis and the potential benefit of simultaneous inhibition of these pathways in neuroprotection and axonal regeneration in an ON crush injury model.
RESULTS

ON injury induces caspase activation and increases RIP kinase expression
The initiation of RGC death after ON damage has been linked to the disruption of retrograde axonal transport (27) and activation of the dual-leucine kinase pathway (28, 29) , and is widely used as a model of RGC death in glaucoma (30). Here, we evaluated changes in known effectors of cell death following optic nerve injury, including caspases as mediators of apoptosis and RIP kinase as a mediator of necrosis (10). One day after ON injury (vehicle), the activities of caspase-8, -9 and -3 were significantly increased compared with those in non-injured retina ( Figure 1A ). RIP3 is a key regulator of RIP1 kinase activation, and its expression level has been shown to correlate with responsiveness to programmed necrosis (12). Quantitative real-time PCR analysis revealed that RIP3 and RIP1 expression in the retina increased up to 9-and 5-fold, respectively, 1 day after ON injury compared with those in non-injured retina ( Figure 1B ). Western blot analysis of retina extracts confirmed the up-regulation of RIP3 and RIP1 expression after ON injury compared with non-injured retina ( Figure 1C ). These results suggest that both caspase and RIP kinase pathways may contribute to RGC death after ON injury.
Individual and combined treatment of caspase and RIP1 kinase inhibitor suppresses
RGC death after ON injury
To further investigate the role of caspases and RIP kinases in RGC death after ON injury, we used a pan-caspase inhibitor, ZVAD (benzoyl-Val-Ala-Asp-fluoromethyl ketone) and a RIP1 kinase inhibitor, Necrostatin-1 (Nec-1). TUNEL (+) cells in the retinal ganglion cell layer (GCL) were assessed 1 day after ON injury, because the number of TUNEL (+) cells peaked at this time point (Figure 2A and 2B) . Although TUNEL has been used as a marker of apoptosis, several studies have indicated that necrosis, programmed or otherwise, also yields DNA fragments that react with TUNEL, rendering it difficult to distinguish between apoptosis and necrosis (14, 31). Intravitreal injection of ZVAD (300 μM) decreased the activities of caspase-8, -9 and -3 by approximately 60%; however, caspase inhibition with ZVAD did not significantly alter the number of TUNEL (+) cells (Figure 2A and 2B) . Administration of Nec-1 alone also failed to show a significant protective effect. However, co-treatment with ZVAD and Nec-1 resulted in a dramatic decrease of TUNEL (+) cells 1 day after ON injury ( Figure 2A and 2B).
We next evaluated the injury and loss of RGCs after ON damage by performing immunofluorescence for the specific RGC marker, Brn3b, which is downregulated after nerve damage and precedes RGC loss, and by measuring inner plexiform layer (IPL) thickness. Significant decreases of Brn3b (+) expression and IPL thickness ratio were first observed at 3 days after ON injury and progressed by 7 days ( Figure 2C -2E) Treatment with ZVAD or Nec-1 alone failed to rescue RGC loss at 7 days after ON injury, However, co-administration of ZVAD and Nec-1 markedly suppressed the decrease in Brnb3 (+) cells and IPL thickness ratio ( Figure 2C-2E ). Administration of ZVAD alone, Nec-1 alone, or ZVAD plus Nec-1 did not affect the TNF-α expression levels after ON injury. Taken together, these data suggest that inhibition of both caspases and RIP1 kinase is required for effective neuroprotection after ON injury, at least in the short term.
Programmed Necrosis is involved in RGC death after ON injury and is exacerbated by inhibition of apoptosis
Next, we investigated the morphology of dying RGCs by transmission electron microscopy (TEM). RGC death was categorized into apoptosis, necrosis and unclassified end-stage of death, as previously described (14). One day after ON injury, both apoptotic and necrotic RGCs were observed in the vehicle-treated retina (apoptotic cells: 13.4 ± 5.8%, necrotic cells: 16.9 ± 4.2%, unclassified: 2.2 ± 2.4%; Figure 3A and 3B). Nec-1 treatment slightly decreased necrotic RGC death (% apoptotic cells: 13.0 ± 8.4%, necrotic cells: 10.6 ± 2.6%, unclassified: 1.0 ± 1.8%; Figure 3A and 3B). In contrast, ZVAD treatment significantly decreased apoptotic RGC death, while it increased necrotic cell death without reducing overall cell loss (% apoptotic cells: 5.6 ± 3.4%, P < 0.01; necrotic cells: 30.7 ± 4.9%, P < 0.01; unclassified: 3.4 ± 2.3; Figure 3A and 3B). In addition, infiltration of inflammatory cells was more prevalent in ZVAD-treated retina ( Figure 3A ).
Co-administration of ZVAD and Nec-1 led to a substantial decrease of both apoptotic and necrotic RGC death (% apoptotic cells: 4.2 ± 5.1%, P < 0.01; necrotic cells: 9.8 ± 6.6%, P < 0.01; unclassified: 1.8 ± 1.8%; Figure 3A and 3B).
Consistent with TEM results, intravitreal injection of propidium iodide (PI), a membrane-impermeant dye which detects cells with disrupted cell membrane (32), showed increased numbers of PI (+) cells in ZVAD-treated retina compared with vehicletreated retina after ON injury ( Figure 3C and 3D) . In contrast, the number of PI (+) cells was significantly decreased by co-administration of ZVAD plus Nec-1 ( Figure 3C and 3D). Collectively, these results demonstrate that RIP1 kinase-mediated necrosis is an important pathway of RGC death in addition to apoptosis, and compensates for blockade of caspase-dependent apoptosis after ON injury.
Rip3 deficiency prevents necrosis induction and attenuates RGC loss after ON injury
To further elucidate the role of RIP1 kinase in RGC death after ON injury, we used mice deficient for Rip3, since Rip1 -/-mice die postnatally at day 1-3 (33). Rip3 These data confirm that RIP kinases play an essential role in the induction of necrosis after ON injury.
RIP kinases mediate ROS production after ON injury
Recent studies have shown that RIP kinases induce programmed necrosis via reactive oxygen species (ROS) overproduction (11, 13, 34) . One day after ON injury, retinal oxidative damage, as assessed by ELISA for carbonyl adducts of proteins, increased significantly compared with untreated retina ( Figure 5 ). Interestingly, ZVAD administration enhanced retinal oxidative damage, suggesting that RIP kinase activation may promote ROS overproduction (14). Indeed, co-administration of ZVAD and Nec-1 or Rip3 deficiency substantially decreased retinal oxidative damage after ON injury ( Figure 5 ).
These results indicate that RIP kinases play a crucial role in ROS production.
Long-term effects of inhibiting Caspases and RIP kinases after ON injury.
Given the increased effectiveness of combinatorial treatment noted in the short term (1-7 days), we investigated whether combinatorial treatment also provides longer-term protection for RGCs. For these studies, we applied agents at three time points (immediately after nerve injury and again after 3 days and 7 days) and examined RGC survival at 2 weeks post-crush. As seen in Fig 6A repeated , and repeated intraocular injections of ZVAD increased survival another 40% above this level ( Fig. 6A , P < 0.001). Repeated injections of the vehicle used for Nec-1 alone increased survival by 60% above baseline, and the addition of Nec-1 only augmented survival by another 17% to a total of 44% of normal. Similarly, Rip3 -/-mice exhibited a 64% increase in RGC survival relative to untreated wild-type mice, bringing overall survival only up to 36% normal. Because these mice lack the rip3k gene entirely, the extensive cell loss seen at 2 weeks implies that there is only a minor long-term benefit of preventing necrotic cell death. In addition, in contrast to our short-term experiment, the combination of Nec-1 and ZVAD caused only a marginal increase in RGC survival relative to either Nec-1 or ZVAD alone in the long term (P = 0.08). This result may be due to rapid clearance of these small molecules, or that long-term survival requires suppression of additional celldeath pathways.
Necrostatin aids axonal regeneration.
Inhibitors of caspases-6 and -8 were recently reported to increase the sprouting of injured axons in the optic nerve (20), and even stronger effects were reported after inhibiting
Caspases-2 and -6(22). In our hands, repeated injections of either saline or 1% DMSO were sufficient to induce considerable regeneration, probably due to the induction of an inflammatory response in the eye and subsequent elevation of the atypical growth factor oncomodulin (35) (36, 37). The general caspase inhibitor ZVAD caused no additional increase in regeneration (Fig. 7A ) nor did repeated injections of either z-IETD-FMK, a specific inhibitor of caspase-8, or z-DEVD-FMK, a specific inhibitor or caspase-3 (Suppl . Fig 1) . In contrast, the RIPK1 inhibitor Nec-1 led to substantially more axon regeneration than the vehicle control ( Fig 7B) . The addition of ZVAD to Nec-1 minimally enhanced this effect (Fig. 7C ).
To investigate whether the effects of Nec-1 were mediated through the RIP1-RIP3 interaction, we examined regeneration in Rip3 -/-mice. To our surprise the RIP3 null mice did not exhibit any axonal regeneration, suggesting that other effectors of RIP1K or other targets of Nec-1 may mediate the effects of that agent on axonal regeneration (Fig. 7B ).
DISCUSSION
Considerable evidence suggests that in glaucoma, damage begins within the ON due to structural changes within the lamina cribrosa (38) , leading to cellular changes that influence RGC viability (39). Thus axonal injury has long been studied as model of glaucoma.
Accumulating evidence suggests that TNF-α contributes to neuronal death in glaucoma (19) . TNF-α is elevated in the aqueous humor of glaucoma patients (40), and polymorphisms in TNF-α -related genes are associated with increased risk for glaucoma (41).
Neutralization of TNF-α or deleting the gene encoding TNF-α or one of its receptors (TNFR2) prevents RGC death in several experimental models of glaucoma (16, 19) (17).
However, the mechanism by which TNF-α signaling leads to RGC death remains unclear, and may involve inflammation and Fas ligand as intermediaries (16, 17, (42) (43) (44) (45) (46) (47) (48) .
Other studies have investigated the effects of inhibiting caspases in protecting RGCs and promoting axonal regeneration (20) (21) (22). In general, these studies show that blocking caspases delays but does not fully attenuate the loss of RGCs, and may have some effects on axonal regeneration (20) (21) (22). Over the past years there has been increasing awareness of caspase-independent death pathways and appreciation that cells can die though alternate pathways such as RIPK mediated necrosis. (7, 8, 49) (11-14) , (15). In our study, we found that expression of RIP1 and RIP3, a key activator of RIP1 kinase, was significantly elevated after ON Crush. Tezel et al reported an up-regulation of RIP kinase expression in primary RGC culture after 24hr exposure to TNF-α using cDNA arrays (50). Furthermore, we demonstrated that Nec-1, which targets RIP1 phosphorylation, and Rip3 deficiency (11, 51), suppressed RGC death when combined with pancaspase inhibitor. However, at later time points, RGCs continued to die, even when Nec-1 was combined with caspase inhibitors. Thus, although RIP1 kinase contributes to RGC death, alternative death pathways that are unaffected by our treatments appear to remain active.
Although the presence of necrosis as well as apoptosis was reported in previous morphological analysis of RGC death in experimental glaucoma (52, 53), most recent studies have not focused on necrosis since it has been considered a passive, unregulated form of cell death. In this study, we showed that blockade of caspases with ZVAD decreased apoptosis but exacerbated necrotic RGC death. Furthermore, early necrotic changes were reversed after Nec-1 co-administration. These findings clearly identify RIP kinase-mediated necrosis as an important and complementary mechanism of RGC death that acts in parallel with caspase-dependent apoptosis.
Most previous studies on neuroprotection have shown the effect to be short term.
We hypothesized that combination therapy might result in longer lasting effects. However our experiments demonstrated that our long-term effects were muted. This could be a result of pharmacokinetics, since both caspase inhibitors and necrostatins are small molecules with short half-life (in hours), which precludes frequent injection into the mice eyes. Morever, systemic administration is only feasible for Necrostatin and not the combination, since zVAD does not cross the Blood Brain Barrier. In addition our data suggest that there may be more pathways involved in long term survival of RGCs. An important downstream event of RIP kinase activation is the generation of ROS, which is thought to contribute to necrotic and autophagic cell death. RIP1 kinase has been reported to regulate ROS production both directly and indirectly. First, after TNF-α stimulation, RIP1
forms a complex with NADPH oxidase 1 and produces superoxide during necrosis (34).
Second, activated RIP3 interacts with metabolic enzymes such as glutamate dehydrogenese1 and thereby increases mitochondrial ROS production (13). Third, RIP1
kinase activates autophagic degradation of catalase leading to ROS accumulation (54). In fact, we observed that ROS accumulation after ON injury increased after ZVAD treatment while it decreased with Nec-1 treatment or RIP3 deficiency ( Figure 5 ). Thus, it is possible that to have effective long term neuroprotection autophagy and ROS may need to be modulated.
Surprisingly we observed that Nec-1 promotes axonal regeneration. Previous studies have shown that inhibition of caspase-6 or -8 stimulates a modest amount of axonal sprouting past the site of ON injury (20) and that inhibition of caspases-2 and -6 has a more substantial effect(22) . In our studies, neither the pan-caspase inhibitor ZVAD nor the caspase-8-specific inhibitor
showed an effect over and above the vehicle. In contrast, Necrostatin exerted a more substantial effect on regeneration, which was minimally augmented by the addition of pan-caspase inhibitors. Surprisingly, although
Nec-1 alone resulted in axonal regeneration, Rip3-/-mice did not exhibit any. This could be due to the fact that Nec-1 is a RIP1 kinase inhibitor and thus effectors of RIP1 Kinase other than Rip3 may mediate the observed effect, or that other, as yet unknown targets of Nec-1 may be responsible for axonal rgenration.
The concept of neuroprotection, i.e., the prevention of RGC death as a potential treatment for glaucoma patients who do not respond to current IOP lowering modalities or present with normal IOP, has become an extensive research field in glaucoma. Several neuroprotective drug-based monotherapy approaches have been proposed without showing any significant clinical efficacy (55-57). Our findings reveals the complexity and the redundancy of cell death pathways and suggests that multiple approaches may be required for effective RGC death prevention. Our study supports the idea that Nec-1 may act in a complementary fashion to other treatments that augment RGC survival and axon
regeneration, yet even when identified apoptotic and necrotic pathways are blocked, RGC death continues. These results suggest the need to identify additional suppressors of cell death and stimulants of cell survival. Plains, NJ) before all experimental manipulations.
EXPERIMENTAL PROCEDURES Animals
Mouse models of RGC loss
We utilized two animal models of RGC death. In the ON injury model, mice were anesthetized and subjected to severe crush injury at 1 mm distance from the eyeball for 15 sec using a cross-action forceps taking special care not to interfere with the blood supply (59). Injured mice were randomly divided into 4 groups for treatment: vehicle group (0.5% DMSO and 0.8% cyclodextrin in PBS, n = 6), ZVAD group (300 ⎧ M; Alexis, Plymouth Meeting, PA, n = 6), Nec-1 group (4 mM; a kind gift from Dr. J. Yuan, Harvard Medical School, Boston, MA, n = 6), and ZVAD plus Nec-1 group (n = 6). Soon after injury, each group received an intravitreal injection (2 ⎧ l) with the respective compounds..
Quantification of RGC survival and measurement of IPL thickness
At indicated timepoints, eyes were enucleated and RGC loss was quantified from histological sections of mouse retina. Only transverse sections involving the optic disc were used for analysis and the fields corresponding to approximately 400 ⎧ m of both sides of retina extending from the ON head (2 points/section x 3 sections per eye, n = 6) were examined with an optical microscope (x40 objectives) ( Figure S2 ). IPL thickness was measured with OpenLab software (Open Lab, Florence, Italy) (2 points/section x 3 sections per eye, n = 6). The ratio of IPL thickness was then calculated as a percentage of IPL thickness in the normal mouse eyes (n = 6).
Quantitative real-time PCR
Total RNA extraction, cDNA synthesis and PCR amplification have been performed as previously reported (60). A real-time PCR assay was performed with Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). The primers are shown in Table S1 . For relative comparison of each gene, we analyzed the Ct value of real-time PCR data with the Δ Δ Ct method normalizing by an endogenous control (®-actin).
ELISA
The protein contents in retinal extract were determined with ELISA kits for protein carbonyls (Cell Biolabs, San Diego, CA) according to the manufacturer's instructions.
Western Blotting
Whole retinas were harvested and lysed for 30 min on ice in lysis buffer (50 mM Tris- Table 1 .
Immunohistochemistry
Immunohistochemistry was performed as previously reported (60). After fixation and permeabilization, the sections were incubated with one of the primary antibodies (Table   S1 ). An appropriate fluorophore-conjugated secondary antibody (Molecular Probes, Carlsbad, CA) was used to detect fluorescence using a confocal microscope (Leica Microsystems, Wetzler, Germany).
Measurement of caspases-8, -9 and -3 activities
The activities of caspase-8, -9 and -3 were measured with the use of a commercially available kit according to the manufacturer's instructions (APT171/131/139; Millipore, Billerica, MA). One day after injury, activities in the ON injured mice treated with vehicle, ZVAD, Nec-1 or ZVAD plus Nec-1 were normalized to their corresponding activities in non-ON injured retina (normal).
TUNEL Analysis
TUNEL and quantification of TUNEL (+) cells were performed as previously described (61) death. Autophagosomes were defined as a double-or multi-membraned structure containing cytoplasmic material and/or organelles, and autolysosome was defined as cytoplasmic vesicle containing electron dense degraded material, as previously described (62). 
14 days after optic nerve injury, mice were sacrificed with an overdose of sodium pentobarbital and were perfused with saline and 4% paraformaldehyde 
Statistical Analysis
All values were expressed as the mean ± SD. Statistical differences between two groups were analyzed by Mann-Whitney U test. Multiple group comparison was performed by ANOVA followed by Tukey-Kramer adjustments. Differences were considered significant at P < 0.05. (
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. . C-E, Immunofluorescent staining for Brn3b (green) and PI (red) (C), quantification of Brn3b (+) cells (D) and IPL thickness ratio (E). The decrease of Brn3b (+) cells and IPL thickness ratio after ON injury was markedly suppressed by treatment of ZVAD plus Nec-1 (n = 6-8, *p < 0.01).
Bars: (A, C) 100 ⎧ m.
GCL; retinal ganglion cell layer, IPL; inner plexiform layer, INL; inner nuclear layer, ONL; outer nuclear layer. GCL; retinal ganglion cell layer, INL; inner nuclear layer, ONL; outer nuclear layer. and Rip3 -/-mice (black box) (B). The eyes treated with vehicle, ZVAD, Nec-1, or ZVAD plus Nec-1 were analyzed 1 day after ON injury. Rip3 -/-mice exhibited significantly less TUNLE (+) cells than WT mice, and this protective effect was augmented by ZVAD treatment (n = 4, *p < 0.01, NS; not significant). GCL; retinal ganglion cell layer, IPL; inner plexiform layer, INL; inner nuclear layer, ONL; outer nuclear layer.
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Figure 5. RIP kinase inhibition prevents ROS production after ON injury
ELISA to evaluate carbonyl contents 1day after ON injury. Non-injured retina was used as a control (n = 4, *p < 0.01, NS; not significant). WT (white box) or Rip3 -/-mice (black box) were treated with vehicle, ZVAD, Nec-1 or ZVAD plus Nec-1, and the retinas were collected 1 day after ON injury. After ON injury, carbonyl contents increased, and this increase was further enhanced by ZVAD. Nec-1 or Rip3 deficiency significantly reduced the increase of carbonyl contents after ON injury (n = 4, *p < 0.01, NS; not significant). 1 
Fig 7 Necrostatin increases Axonal Regeneration independently of Rip3 inhibition
The general caspase inhibitor ZVAD caused no additional increase in regeneration over the vehicle control (7A). In contrast, the RIPK1 inhibitor Nec-1 led to more axon regeneration than the vehicle control (7B). The addition of ZVAD to Nec-1 did not enhance this effect (Fig. 7C ). To investigate whether the effects of Nec-1 were mediated through the RIP1-RIP3 interaction, we examined regeneration in Rip3 -/-mice. To our surprise the RIP3 null mice did not exhibit any axonal regeneration, suggesting that other effectors of RIP1K or other targets of Nec-1 may mediate the effects of that agent on axonal regeneration (Fig. 7B) . (n=6-8 for each group)
